Cargando…

Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers

INTRODUCTION: Hepatitis B virus (HBV) infection is associated with the onset of several major liver diseases. Inactive hepatitis B surface antigen (HBsAg) carriers (IHCs) may be successfully treated with PEGylated interferon-α2b (PEG-IFNα2b)-based antiviral therapy; however, studies on this treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yan, Qi, Min, Liao, Chengjin, Xun, Jinrui, Zou, Ju, Huang, Haiyue, Long, Li-Yuan, Chen, Jun, Fan, Xuegong, Chen, Ruochan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572934/ https://www.ncbi.nlm.nih.gov/pubmed/34350562 http://dx.doi.org/10.1007/s40121-021-00511-w

Ejemplares similares

Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis
por: Song, Aixin, et al.
Publicado: (2021)

Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B
por: Chen, Ruochan, et al.
Publicado: (2022)

Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers
por: Li, Hong, et al.
Publicado: (2022)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

Improved Efficacy of a Pegylated Interferon-α-2a Stepwise Optimization Treatment Strategy in the Treatment of Hepatitis B e Antigen-positive Chronic Hepatitis B Patients
por: Zhou, Pu, et al.
Publicado: (2015)

Hepatitis B Virus: Inactive carriers
por: Sharma, Sanjeev Kumar, et al.
Publicado: (2005)

Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients
por: Liu, Yong Zhe, et al.
Publicado: (2012)

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
por: Liem, Kin Seng, et al.
Publicado: (2019)

Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C
por: Hu, Jing-Hong, et al.
Publicado: (2019)

Transcriptomic Analysis of Livers of Inactive Carriers of Hepatitis B Virus With Distinct Expression of Hepatitis B Surface Antigen
por: Rico Montanari, Noe, et al.
Publicado: (2021)

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B
por: Zhang, Wenhong, et al.
Publicado: (2018)

Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
por: Groves, M D, et al.
Publicado: (2009)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Pegylated interferon/telbivudine sequential therapy in Hepatitis Be antigen negative severe chronic hepatitis B patient
por: Caroleo, Benedetto, et al.
Publicado: (2013)

Inactıve hepatitis B surface antigen carriers and intrafamilial tramsmission: results of a 10-year study
por: Demirturk, Nese, et al.
Publicado: (2014)

Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)
por: Jun, Dae Won, et al.
Publicado: (2018)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection
por: Vasconcelos, Joana, et al.
Publicado: (2022)

Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients
por: Broquetas, Teresa, et al.
Publicado: (2020)

Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B
por: Su, Qian, et al.
Publicado: (2018)

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy
por: Yoshida, Kanako, et al.
Publicado: (2021)

Effect of pegylated interferon-α2b add-on therapy on renal function in chronic hepatitis B patients: A real-world experience
por: Peng, Mei-Juan, et al.
Publicado: (2022)

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
por: Chen, Ruochan, et al.
Publicado: (2021)

CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients
por: Chen, Jiaxuan, et al.
Publicado: (2023)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Inactive Carriers of Hepatitis B Virus: A Never Ending Story
por: Macedo, Guilherme
Publicado: (2015)

Hepatitis B Virus Inactive Carriers: Which Follow-up Strategy?
por: Magalhães, Maria João, et al.
Publicado: (2015)

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
por: Daud, A. I., et al.
Publicado: (2010)

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
por: Pennisi, Manuela, et al.
Publicado: (2017)

Use of a Deep Learning Approach for the Sensitive Prediction of Hepatitis B Surface Antigen Levels in Inactive Carrier Patients
por: Kamimura, Hiroteru, et al.
Publicado: (2022)

Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2021)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020)

Thrombotic thrombocytopenic purpura developed after pegylated interferon treatment for hepatitis B infection
por: Mei, Shuqin, et al.
Publicado: (2022)

Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis
por: Wang, Yin-Chen, et al.
Publicado: (2016)

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
por: Huang, Yi-Wen, et al.
Publicado: (2022)

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment
por: Li, Ming-Hui, et al.
Publicado: (2017)

Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C
por: Ding, Yan-Hua, et al.
Publicado: (2017)

Liver in infections: a single-cell and spatial transcriptomics perspective
por: Zou, Ju, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_up3uascstmja4paso934151o3u